Natera Inc (NTRA)
107.32
+3.57 +3.44%
NASDAQ
Apr 13, 20:00
USD
Natera Average Diluted Shares Outstanding (Quarterly)
View 4,000+ financial data types
Browse...
View Full Chart
Average Diluted Shares Outstanding (Quarterly) Chart
Historical Average Diluted Shares Outstanding (Quarterly) Data
View and export this data going back to 2014.
Start your Free Trial
Export Data
Date Range:
Data for this Date Range | |
---|---|
Dec. 31, 2020 | Upgrade |
Sept. 30, 2020 | Upgrade |
June 30, 2020 | Upgrade |
March 31, 2020 | Upgrade |
Dec. 31, 2019 | Upgrade |
Sept. 30, 2019 | Upgrade |
June 30, 2019 | Upgrade |
March 31, 2019 | Upgrade |
Dec. 31, 2018 | Upgrade |
Sept. 30, 2018 | Upgrade |
June 30, 2018 | Upgrade |
March 31, 2018 | Upgrade |
Dec. 31, 2017 | Upgrade |
Sept. 30, 2017 | Upgrade |
June 30, 2017 | Upgrade |
March 31, 2017 | Upgrade |
Dec. 31, 2016 | Upgrade |
Sept. 30, 2016 | Upgrade |
June 30, 2016 | Upgrade |
March 31, 2016 | Upgrade |
Dec. 31, 2015 | Upgrade |
Sept. 30, 2015 | Upgrade |
June 30, 2015 | Upgrade |
March 31, 2015 | Upgrade |
Dec. 31, 2014 | Upgrade |
Sept. 30, 2014 | Upgrade |
June 30, 2014 | Upgrade |
March 31, 2014 | Upgrade |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
View Average Diluted Shares Outstanding (Quarterly) for NTRA
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
Start your free 7-Day Trial.
Start My Free Trial
No credit card required.
Already a subscriber? Sign in.
Advertisement
Average Diluted Shares Outstanding Definition
The Average Diluted Shares Outstanding is the amount of shares outstanding after all conversion possibilities are implemented over the reporting period.
Average Diluted Shares Outstanding (Quarterly) Benchmarks
Exact Sciences Corp | Upgrade |
Illumina Inc | Upgrade |
Lantheus Holdings Inc | Upgrade |
Average Diluted Shares Outstanding (Quarterly) Range, Past 5 Years
Minimum | Upgrade | Jun 2016 |
Maximum | Upgrade | Dec 2020 |
Average | Upgrade |
News
Illumina upgraded at Canaccord Genuity with readthrough to other firms on FTC challenge
SA Breaking News 03/31 10:51 ET
SA Breaking News 03/31 10:51 ET
Natera Signs Strategic Collaboration on Prenatal Genetic Testing With Tesis Labs; Shares Rise Early
MT Newswires 03/31 09:49 ET
MT Newswires 03/31 09:49 ET
Natera and Tesis Labs ink strategic collaboration on prenatal genetic testing
SA Breaking News 03/31 09:14 ET
SA Breaking News 03/31 09:14 ET
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing
PR Newswire 03/31 09:07 ET
PR Newswire 03/31 09:07 ET
Natera's Signatera test granted two FDA Breakthrough Device Designations
SA Breaking News 03/24 09:34 ET
SA Breaking News 03/24 09:34 ET
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test
PR Newswire 03/24 09:03 ET
PR Newswire 03/24 09:03 ET
Natera Discloses Patient Screening Using Signatera for Bladder Cancer Study
MT Newswires 03/10 11:07 ET
MT Newswires 03/10 11:07 ET
Natera and Genentech initiate late-stage muscle-invasive bladder cancer trial
SA Breaking News 03/10 09:25 ET
SA Breaking News 03/10 09:25 ET
--Analyst Actions: Morgan Stanley Adjusts Price Target on Natera to $140 From $87, Maintains Overweight Rating
MT Newswires 03/01 11:03 ET
MT Newswires 03/01 11:03 ET
Advertisement